Idursulfase

LoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director

Retrieved on: 
Tuesday, January 25, 2022
Entrepreneurship, Research, Service, Metachromasia, Patient, Metachromatic leukodystrophy, Huntington's disease, Disease, Degenerative disease, Neurodegeneration, DNA mismatch repair, Idursulfase, CEO, Hereditary angioedema, COVID-19, Eli Lilly, Gaucher's disease, DNA, Hunter syndrome, Public health, MMR, Therapy, OBE, Company, Lanadelumab, Drug development, Glycogen storage disease, Lists of diseases, Board, Pharmaceutical industry, Pfizer, Moderna, Alfa Romeo, Takeda

CAMBRIDGE, England, Jan. 25, 2022 /PRNewswire/ -- LoQus23 Therapeutics Ltd. ('LoQus23'), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases, announces the appointment of Dr. Melanie Ivarsson, OBE, as Non-Executive Director of the Board.

Key Points: 
  • CAMBRIDGE, England, Jan. 25, 2022 /PRNewswire/ -- LoQus23 Therapeutics Ltd. ('LoQus23'), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases, announces the appointment of Dr. Melanie Ivarsson, OBE, as Non-Executive Director of the Board.
  • David Reynolds, CEO and Co-Founder of LoQus23, said: "On behalf of the board I'd like to welcome Melanie to LoQus23.
  • With these factors combined, LoQus23 has the potential to become a frontrunner in this important disease area."
  • LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches.

LoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director

Retrieved on: 
Tuesday, January 25, 2022
Entrepreneurship, Research, Service, Metachromasia, Patient, Metachromatic leukodystrophy, Huntington's disease, Disease, Degenerative disease, Neurodegeneration, DNA mismatch repair, Idursulfase, CEO, Hereditary angioedema, COVID-19, Eli Lilly, Gaucher's disease, DNA, Hunter syndrome, Public health, MMR, Therapy, OBE, Company, Lanadelumab, Drug development, Glycogen storage disease, Lists of diseases, Board, Pharmaceutical industry, Pfizer, Moderna, Alfa Romeo, Takeda

CAMBRIDGE, England, Jan. 25, 2022 /PRNewswire/ -- LoQus23 Therapeutics Ltd. ('LoQus23'), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases, announces the appointment of Dr. Melanie Ivarsson, OBE, as Non-Executive Director of the Board.

Key Points: 
  • CAMBRIDGE, England, Jan. 25, 2022 /PRNewswire/ -- LoQus23 Therapeutics Ltd. ('LoQus23'), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases, announces the appointment of Dr. Melanie Ivarsson, OBE, as Non-Executive Director of the Board.
  • David Reynolds, CEO and Co-Founder of LoQus23, said: "On behalf of the board I'd like to welcome Melanie to LoQus23.
  • With these factors combined, LoQus23 has the potential to become a frontrunner in this important disease area."
  • LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches.

Iduronate 2 Sulfatase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Professional services, Consulting, Enzymes, Iduronate-2-sulfatase, Sulfatase, Arylsulfatase, IDS, Idursulfase, Hunter syndrome

The "Iduronate 2 Sulfatase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Iduronate 2 Sulfatase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Iduronate 2 Sulfatase - Pipeline Review, H2 2019'; Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 10 molecules.
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome.
  • The report 'Iduronate 2 Sulfatase - Pipeline Review, H2 2019' outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment, By Region And Segment Forecasts, 2019 - 2026

Retrieved on: 
Wednesday, December 4, 2019
Syndromes, Iduronate-2-sulfatase, Mucopolysaccharidosis, Hunter syndrome, Branches of biology, Health, Idursulfase, Sulfatase, Medicine

Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Region, And Segment Forecasts, 2019 - 2026

Key Points: 
  • Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Region, And Segment Forecasts, 2019 - 2026
    The global hunter syndrome treatment market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%.
  • Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme.
  • Shire plc's Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma's Hunterase (idursulfase beta) being approved only in South Korea.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug

Retrieved on: 
Thursday, April 4, 2019
Branches of biology, Brain, Organ systems, Health, Green Cross, Iduronate-2-sulfatase, Pharmacokinetics, Hunter syndrome, ICV, Idursulfase, IDS, Sulfatase

and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome.

Key Points: 
  • and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome.
  • Used as one of the methods for Hunter syndrome treatment, intravenous injection does not penetrate the blood brain barrier in clinically adequate amounts.
  • Hunterase (Idursulfase-beta) ICV developed by GC Pharma is delivered directly to cerebral ventricles by intracerebroventricular (ICV) administration, in order to reach the cells of the brain and central nervous system.
  • "We are delighted to further enhance the value of Hunterase through this partnership," said Eun Chul Huh, Ph.D., President at GC Pharma.